Retatrutide: FDA status, clinical trial results, and the risks of "research peptide" versions
Retatrutide, sometimes called "reta" or "GLP-3" online, is the weight-loss medicine patients ask us about most this year. The trial results are impressive. But retatrutide is not FDA approved, and the vials being sold online as "research chemicals" are not the medicine being studied. Here's where it stands, what the studies show, and why we strongly advise against buying it online.
What is retatrutide?
Retatrutide is an investigational, once-weekly injection developed by Eli Lilly and Company. Current medicines work on one or two gut hormone pathways: semaglutide (Ozempic, Wegovy) acts on GLP-1, and tirzepatide (Mounjaro, Zepbound) acts on GLP-1 and GIP. Retatrutide is a "triple agonist" that acts on three receptors:
- GLP-1, which reduces appetite, slows stomach emptying, and helps control blood sugar.
- GIP, which works alongside GLP-1 on appetite and insulin release.
- Glucagon, which may increase the calories your body burns and help reduce liver fat.
Researchers think the added glucagon effect is one reason weight loss in the trials has been larger than with current medicines.
Is retatrutide FDA approved?
No. As of November 9, 2026, retatrutide is not approved by the FDA or by any other regulatory agency in the world. It's available only to people enrolled in clinical trials. Here's where the approval process stands:
- Phase 3 trials: Lilly has reported positive results from six Phase 3 trials. More are still running, including a head-to-head trial against tirzepatide and a large, roughly five-year trial of heart and kidney outcomes that's expected to finish around 2029.
- Submission: Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027, once its manufacturing data package is complete. It hasn't been submitted yet.
- Review: FDA review usually takes about 10 to 12 months after submission. If it's approved, retatrutide would most likely reach pharmacies in late 2027 or 2028. Approval isn't guaranteed.
- A legal question: Lilly and the FDA disagree about whether retatrutide should be regulated as a "biologic" or as a standard drug. The FDA most recently ruled it's a drug, on October 2, 2026, and Lilly has appealed. This dispute affects which type of application Lilly files and how long it has market exclusivity. It isn't about safety.
What the studies show
Most of the results below come from Lilly's announcements of top-line results. Full data are being presented at medical meetings and published in peer-reviewed journals. Weight loss figures are averages for people who stayed on treatment, and individual results varied widely.
- Phase 2 (published 2023): adults with obesity lost an average of up to 24% of their body weight at 48 weeks on the highest dose. This was the result that first drew attention to the drug.
- TRIUMPH-4 (obesity and knee osteoarthritis): average weight loss of 28.7% at 68 weeks on the 12 mg dose, with improvement in knee pain.
- TRIUMPH-1 (2,339 adults with obesity or overweight): at 80 weeks, average weight loss was about 19% on 4 mg, 26% on 9 mg, and 28% on 12 mg, compared with about 4% on placebo. In a two-year extension, people with more severe obesity lost up to about 30%. The trial also showed improvements in obstructive sleep apnea and knee pain.
- TRIUMPH-2 (obesity with type 2 diabetes): up to 20.8% average weight loss at 80 weeks, and A1C fell by 1.4 to 1.6 points from an average of 7.7%.
- TRIUMPH-3 (severe obesity with heart disease): up to 22.6% average weight loss at 80 weeks, with lower triglycerides, non-HDL cholesterol, blood pressure, and inflammation markers. The trial wasn't designed to show fewer heart attacks or strokes, and it didn't show a clear difference in those events. The dedicated outcomes trial is still underway.
- TRANSCEND-T2D-1 (type 2 diabetes): 16.8% average weight loss at 40 weeks on 12 mg, with meaningful A1C reductions.
- TRANSCEND-T2D-2 (head-to-head with Ozempic 2 mg, type 2 diabetes): at 80 weeks, A1C fell 2.2 points with retatrutide versus 1.8 with Ozempic, and weight loss was 19.5% to 20.9% versus 9.4%. This trial was open-label, so participants knew which drug they were taking.
Side effects seen in the trials
Retatrutide's side effects resemble those of other GLP-1 medicines, but they were common, especially at higher doses. In TRIUMPH-1, people on the highest dose reported:
- Nausea: about 42%
- Diarrhea: about 32%
- Constipation: about 26%
- Vomiting: about 25%
Most stomach symptoms were mild to moderate and happened while the dose was being increased. Researchers also noted dysesthesia, an abnormal or uncomfortable skin sensation such as tingling or burning, in up to about 1 in 10 people on higher doses, along with more urinary tract infections. These were mostly mild, and most resolved during treatment.
Depending on the trial, roughly 8% to 14% of people on the 12 mg dose stopped because of side effects, compared with about 5% on placebo. Long-term safety, including effects on the heart, kidneys, muscle, and bone with very large weight loss, is still being studied. Lilly's trials raised doses slowly, every four weeks, with medical monitoring.
The warning: "research chemical" retatrutide is not the real medicine
Because retatrutide isn't available yet, an online gray market has grown up around it. Websites, social media accounts, and some telehealth companies sell vials of powder or liquid labeled "retatrutide," "reta," or "GLP-3," usually marked "for research use only" or "not for human consumption." Some advertise "compounded retatrutide." Here's what patients should know:
- It can't be legally sold for human use. Lilly is the only lawful maker of retatrutide, and it says no product sold to consumers is genuine. Lilly has also filed lawsuits against sellers.
- It can't be legally compounded. The FDA has stated that retatrutide cannot be used in compounding under federal law. A prescription or a pharmacy license doesn't change that.
- The FDA has taken action. The agency has sent warning letters to sellers of unapproved retatrutide, concluding that "research use only" labels don't change what is clearly being marketed for people to inject. It advises consumers not to buy these products.
- You don't know what's in the vial. These products are mostly made overseas without FDA oversight. A vial may contain too much drug, too little, a different substance, contaminants, or bacteria if it isn't sterile. A "certificate of analysis" describes a tested sample, not necessarily the vial you receive.
- Dosing errors are easy to make. Mixing powder and measuring doses with insulin syringes without medical guidance can lead to large overdoses. Higher doses mean more severe vomiting, dehydration, and a higher chance of complications.
- Serious harms have been reported. Consumer watchdog groups and news outlets have reported adverse events, including hospitalizations, in people using products sold as retatrutide. In October 2026, CBS News reported that the FDA had received two reports of deaths after people used such products, although those reports hadn't been confirmed.
- No one is watching your health. Retatrutide can raise heart rate and affects blood sugar, digestion, and other organs. Without a medical evaluation, important risks, drug interactions, and early warning signs can be missed.
The trial results describe Lilly's carefully manufactured drug given under close medical supervision. They don't apply to an unregulated vial bought online.
If you've already used an online product
- Don't take another dose until you've talked with a physician or pharmacist. Keep the vial and its packaging so your clinician can see exactly what you used.
- Be honest with your healthcare team about what you took and how much. We won't judge you, and we need the information to keep you safe.
- Get urgent medical care for severe or persistent abdominal pain (especially pain that spreads to your back), repeated vomiting, inability to keep fluids down, signs of dehydration, fainting, chest pain, a racing heartbeat, yellowing of the skin or eyes, or signs of an allergic reaction such as swelling or trouble breathing. Call 911 in an emergency.
- You or your clinician can report side effects to the FDA's MedWatch program at fda.gov/medwatch.
Safe ways to get effective treatment now
If you're interested in retatrutide, you have two legitimate options today. You can look for a clinical trial at ClinicalTrials.gov. Or you can start with an FDA-approved medicine. Tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and the newer once-daily pill orforglipron (Foundayo) produce meaningful weight loss and have established safety records. Whether one is right for you depends on your health history, your goals, and your insurance coverage.
Medical weight loss at Lakewood Ranch Concierge
Lakewood Ranch Concierge does not prescribe, sell, supply, or administer retatrutide, and we don't recommend obtaining it outside a clinical trial. When it's medically appropriate, we prescribe FDA-approved medications as part of our PHIT (Physical Health Integration Program) medical weight loss program. PHIT is a 12-month plan built around your metabolism, with resting metabolic rate and VO2 max testing up to four times a year, monthly provider visits, and personalized nutrition and exercise guidance. Medications are billed separately. We'll keep following retatrutide and can talk with you about whether it might fit your plan if it's approved. Call or text (941) 237-0129 to get started, or see our membership options.
Frequently asked questions
Is retatrutide FDA approved?
No. Retatrutide is investigational and hasn't been approved by the FDA or any other regulator. Lilly plans to submit it to the FDA in early 2027.
When will retatrutide be available?
No date has been set. Based on Lilly's planned early 2027 submission and typical review times, approval, if granted, would most likely come in late 2027 or 2028.
Is "research grade" or compounded retatrutide legal or safe?
No. Products sold to consumers as retatrutide are unapproved, and the FDA says retatrutide can't be compounded under federal law. Their contents, purity, sterility, and strength are unknown.
How much weight did people lose on retatrutide?
In Phase 3 trials, average weight loss on the highest dose ranged from about 17% to 28% at 40 to 80 weeks, depending on the population, and reached about 30% at two years in people with severe obesity. Results varied from person to person.
Is retatrutide stronger than Ozempic or Zepbound?
In one head-to-head trial in people with type 2 diabetes, retatrutide produced more than twice the weight loss of Ozempic 2 mg. A trial directly comparing it with tirzepatide (Zepbound) is still in progress.
This article is for general educational information only. It isn't medical advice and doesn't establish a physician-patient relationship. Retatrutide is an investigational drug that hasn't been approved by the FDA, and its safety and effectiveness haven't been established outside clinical trials. Trial results described here are largely preliminary, come mainly from the manufacturer, and may change as full data are reviewed. Lakewood Ranch Concierge and its providers do not prescribe, sell, supply, administer, or endorse retatrutide or any unapproved or "research use only" product, and we strongly advise against using such products. Individual results vary, and no specific weight-loss outcome is promised or guaranteed. Information is current as of November 9, 2026, and may change. Brand names mentioned are trademarks of their respective owners, and no affiliation or endorsement is implied. Talk with your own physician before starting, stopping, or changing any medication. For a medical emergency, call 911.